Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenger Organic Weed Killer

Brendan McLaughlin - Process Development & Manufacturing Scientist - Avenge Bio

avengebio (@AvengeBio) / X

avengebio (@AvengeBio) / X

Commercialization Highlights, Office of Technology Transfer, Office of Research

Biotech, Pharmaceutical and Clinical Research News

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial

Zeke Johnston - Senior Director, External Manufacturing and Supply Chain - Avenge Bio

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio on LinkedIn: Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian…

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio, Inc. Company Profile: Financials, Valuation, and Growth